New gout pill HEC93077 passes first safety check in humans
NCT ID NCT05127772
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested an experimental drug called HEC93077 in 126 healthy volunteers and people with high uric acid (gout). The goal was to check safety, how the body processes the drug, and the effect of food. Participants took single or multiple doses for up to 14 days. Results will guide future studies on whether this drug can help control gout.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HEC93077 (an experimental oral drug to lower uric acid)
What this could lead to
If successful, this could lead to a new daily pill to control uric acid levels and prevent gout attacks.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, not on proving the drug works. Many drugs fail in later, larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Universicity Care of Luzhong Hospital
Zibo, Shandong, 255400, China